Executive interview – Cantargia

Published on 28 February 2019

Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing antibodies against target IL1RAP to treat cancer and autoimmune diseases. Lead antibody nidanilimab (previously CAN04) is currently being studied in a Phase I/II study in solid tumours focusing on NSCLC and pancreatic cancer. In this video, the company’s chief executive officer Göran Forsberg introduces the company and lead asset, and provides an overview of R&D progress and expected newsflow.

Share this with friends and colleagues